Compare ARK Genomic Revolution ETF (ARKG) vs First Solar, Inc. (FSLR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ARK Genomic Revolution ETF vs First Solar, Inc. — how do they compare? ARK Genomic Revolution ETF trades at $40.96, while First Solar, Inc. trades at $229.3 (market cap $24.48B). The key difference: ARK Genomic Revolution ETF is trading nearer its 52-week high, First Solar, Inc. nearer its low. Which is the better fit depends on your goals.
| ARKG | FSLR | |
|---|---|---|
Sector | Sector/Thematic | Technology |
52-Week High | $43.57 | $318.30 |
52-Week Low | $23.09 | $160.84 |
Market Cap | — | $24.48B |
Enterprise Value | — | $22.64B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $41.32, down 3.91% today, with a bullish technical signal driven by moving averages. Recent news highlights biotech ETF strength in June 2026, fueled by strong earnings, M&A activity, and AI-driven drug discovery optimism. Key support lies at $40, with resistance at $44.
The outlook remains positive given sector tailwinds, but risks include regulatory hurdles and market volatility. Investor sentiment is buoyed by industry growth catalysts, though selective investment approaches are noted by analysts.
First Solar (FSLR) trades at $227.83, down 0.29% on the day, with a bearish technical signal despite strong fundamentals. The stock shows robust profitability with a 30.73% net income margin and 18.44% ROE, supported by $2.06B in operating cash flow for 2025. Recent earnings beat expectations in Q1 2026 but missed in prior quarters, while a securities class action lawsuit filed in July 2026 adds near-term uncertainty. Valuation metrics appear reasonable with a P/E of 14.72 and P/S of 4.52.
The outlook is mixed: analyst consensus remains bullish with a $271.55 price target (61.64% buy ratings), but legal risks and technical weakness suggest caution. Upside hinges on execution against 2026 guidance of $1.7B net income, while downside risks include litigation outcomes and competitive pressures in solar manufacturing. Cash flow strength and low debt support resilience amid volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About First Solar, Inc.
First Solar designs and manufactures solar photovoltaic panels, modules, and systems for use in utility-scale development projects. The company's solar modules use cadmium telluride to convert sunlight into electricity. This is commonly called thin-film technology. First Solar is the world's largest thin-film solar module manufacturer. It has production lines in Vietnam, Malaysia, the United States, and a new factory under construction in India.
Read more on FSLR →
